• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The TNM system of 1992. Comments from the TNM working group. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.

作者信息

Chisholm G D, Hedlund P O, Adolfsson J, Denis L J, Friberg S, Johansson J E, Peeling B

机构信息

Dept. of Urology, University of Edinburgh, U.K.

出版信息

Scand J Urol Nephrol Suppl. 1994;162:107-14; discussion 115-27.

PMID:7529428
Abstract

The TNM working group acknowledges the multinational agreement reached in the 1992 TNM classification, but nevertheless gives some suggestions for modifications. The main interest of the group has been to evaluate parameters suitable for further ramification of the system. The group found that parameters such as DNA ploidy, PSA, nuclear roundness factor, are not yet ready for this purpose. Grade is an established parameter and should be incorporated into the TNM-categories of localized disease. In metastatic disease a number of parameters are available to subdivide this category according to prognosis, and these will be more uniformly and extensively studied in the several large trials that are now in progress.

摘要

相似文献

1
The TNM system of 1992. Comments from the TNM working group. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Scand J Urol Nephrol Suppl. 1994;162:107-14; discussion 115-27.
2
Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.肿瘤标志物。局限性前列腺癌诊断与预后参数共识会议。瑞典斯德哥尔摩,1993年5月12 - 13日。
Scand J Urol Nephrol Suppl. 1994;162:73-87; discussion 115-27.
3
Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.前列腺癌中细胞DNA测量的临床应用。局限性前列腺癌诊断和预后参数共识会议。瑞典斯德哥尔摩,1993年5月12 - 13日。
Scand J Urol Nephrol Suppl. 1994;162:51-63; discussion 15-27.
4
Prognostic value of serum markers for prostate cancer.前列腺癌血清标志物的预后价值。
Scand J Urol Nephrol Suppl. 2005 May(216):64-81. doi: 10.1080/03008880510030941.
5
College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group.美国病理学家学会关于实体瘤预后标志物临床相关性的第26届会议。前列腺癌工作组报告。
Arch Pathol Lab Med. 1995 Dec;119(12):1122-6.
6
Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.局限性前列腺癌的组织病理学。局限性前列腺癌诊断与预后参数共识会议。瑞典斯德哥尔摩,1993年5月12 - 13日。
Scand J Urol Nephrol Suppl. 1994;162:7-42; discussion 115-27.
7
Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.前列腺特异性抗原/前列腺酸性磷酸酶比值是IV期前列腺癌患者的重要预后因素。
Urology. 2007 Oct;70(4):702-5. doi: 10.1016/j.urology.2007.05.019.
8
p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer.p53表达、增殖标志物Ki-S5、DNA含量及血清前列腺特异抗原:人类前列腺癌可能的生物潜能标志物
Urology. 1996 Aug;48(2):261-8. doi: 10.1016/S0090-4295(96)00169-0.
9
Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.结合活检侧别与TNM分期的改良临床分期系统用于T1c和T2期前列腺癌男性患者:SEARCH数据库的结果
J Urol. 2003 Jun;169(6):2129-35. doi: 10.1097/01.ju.0000065763.21602.14.
10
[Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].[前列腺腺癌在诊断时发生转移的演变及预后因素]
Actas Urol Esp. 1997 Sep;21(8):724-36.

引用本文的文献

1
Prediction of treatment response in head and neck cancer by magnetic resonance spectroscopy.磁共振波谱对头颈癌治疗反应的预测
AJNR Am J Neuroradiol. 2005 Sep;26(8):2108-13.